Altium Capital Management LLC Purchases 173,000 Shares of RxSight, Inc. (NASDAQ:RXST)

Altium Capital Management LLC lifted its stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 154.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 285,000 shares of the company's stock after purchasing an additional 173,000 shares during the period. RxSight makes up about 2.8% of Altium Capital Management LLC's holdings, making the stock its 11th biggest position. Altium Capital Management LLC owned 0.71% of RxSight worth $9,798,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of RXST. Vanguard Group Inc. raised its holdings in shares of RxSight by 4.2% during the fourth quarter. Vanguard Group Inc. now owns 2,383,548 shares of the company's stock valued at $81,946,000 after acquiring an additional 96,464 shares during the period. Artisan Partners Limited Partnership lifted its holdings in shares of RxSight by 32.6% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,551,620 shares of the company's stock valued at $53,345,000 after buying an additional 381,389 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of RxSight by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 830,758 shares of the company's stock valued at $28,568,000 after buying an additional 13,641 shares in the last quarter. State Street Corp increased its holdings in RxSight by 8.3% in the third quarter. State Street Corp now owns 817,671 shares of the company's stock worth $40,417,000 after buying an additional 62,349 shares during the last quarter. Finally, DF Dent & Co. Inc. acquired a new stake in RxSight in the fourth quarter valued at approximately $14,524,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight Stock Down 0.6 %

RxSight stock traded down $0.09 on Friday, hitting $14.43. The company's stock had a trading volume of 1,068,889 shares, compared to its average volume of 618,522. RxSight, Inc. has a one year low of $13.50 and a one year high of $66.54. The firm has a market cap of $584.29 million, a P/E ratio of -17.39 and a beta of 1.26. The company has a fifty day moving average price of $23.77 and a 200-day moving average price of $35.05.

RxSight (NASDAQ:RXST - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). The business had revenue of $40.21 million during the quarter, compared to analyst estimates of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. Analysts anticipate that RxSight, Inc. will post -0.7 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on RXST shares. Piper Sandler started coverage on shares of RxSight in a report on Tuesday. They set a "neutral" rating and a $18.00 price target on the stock. Needham & Company LLC reissued a "buy" rating and issued a $43.00 price target on shares of RxSight in a research report on Thursday, April 3rd. JPMorgan Chase & Co. restated an "underweight" rating and issued a $17.00 price objective (down from $40.00) on shares of RxSight in a research note on Friday, April 4th. Stifel Nicolaus cut their target price on shares of RxSight from $33.00 to $28.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Finally, Bank of America reaffirmed an "underperform" rating and issued a $22.00 price target (down from $36.00) on shares of RxSight in a research report on Thursday, April 3rd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $37.60.

Insider Transactions at RxSight

In other news, Director Tamara Fountain sold 7,000 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the sale, the director now owns 24,793 shares in the company, valued at approximately $637,428.03. This represents a 22.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Shweta Maniar sold 3,519 shares of RxSight stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total value of $108,631.53. Following the completion of the transaction, the director now directly owns 7,383 shares of the company's stock, valued at $227,913.21. This represents a 32.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.36% of the stock is owned by insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.